Oncotarget

In this top-performing paper published in Oncotarget on July 17, 2018, entitled, “A diagnostic autoantibody signature for primary cutaneous melanoma,” Australian researchers developed the first blood test to detect melanoma in early stages.

The researchers from Australia’s Edith Cowan University, Hollywood Private Hospital, Level 1 Melanoma, St. John of God Hospital, Dermatology Specialist Group, Skin Check WA, and The University of Western Australia collected blood sera (plural of serum, which contains exogenous substances in the blood, such as electrolytes, antibodies, autoantibodies, antigens, and hormones) from a total of 245 primary melanoma patients and healthy volunteers. The sera were screened against a high-throughput microarray profiling platform of 1,627 functional proteins. After conducting detailed statistical analysis, the team found that the most effective biomarker for melanoma diagnosis was a combined signature of 10 autoantibodies which, together, displayed 79% sensitivity and 84% specificity in primary melanoma detection.

“This melanoma autoantibody signature may prove valuable for the development of a diagnostic blood test for routine population screening that, when used in conjunction with current melanoma diagnostic techniques, could improve the early diagnosis of this malignancy and ultimately decrease the mortality rate of patients.”

To date, this research paper has since generated an impressive Altmetric Attention score of 597.

Read the full study: https://www.oncotarget.com/article/25669/text/

The Top-Performer series highlights research literature published in Oncotarget that has generated a high Altmetric score. Altmetric scores, located at the top-left of trending Oncotarget papers, provide an at-a-glance indication of the volume and type of online attention the research has received.

Top Oncotarget publications rated by Altmetric score: https://www.oncotarget.com/news/altmetric/

More from the Top-Performer series:

https://www.oncotarget.org/tag/top-performer/

Sign up for free Altmetric alerts about this article:

DOI: https://doi.org/10.18632/oncotarget.25669

Full text: https://www.oncotarget.com/article/25669/text/

Correspondence to: Pauline Zaenker - [email protected]; [email protected]

About Oncotarget:

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget

Facebook - https://www.facebook.com/Oncotarget/

Twitter - https://twitter.com/oncotarget

YouTube - https://www.youtube.com/c/OncotargetYouTube/

LinkedIn - https://www.linkedin.com/company/oncotarget

Pinterest - https://www.pinterest.com/oncotarget/

Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957

In Oncotarget Volume 12, Issue 7 cover paper, titled, "Caloric restriction creates a metabolic pattern of chronological aging delay that in budding yeast differs from the metabolic design established by two other geroprotectors," the researchers conducted a study which compared the metabolic effects of three geroprotectors in budding yeast: calorie restriction, the tor1Δ mutation, and lithocholic acid.

In this study, the researchers from the Department of Biology at Concordia University in Montreal, Quebec, used chronologically aging Saccharomyces cerevisiae—a common budding yeast found in baking, winemaking, and beer brewing. S. cerevisiae is a fungus useful for measuring the mechanisms of aging. The researchers cultured S. cerevisiae in a nutrient-rich medium and compared the metabolic effects of three different geroprotective interventions (both concurrently and separately).

Using liquid chromatography and a tandem mass spectrometry method of non-targeted metabolomics, the team measured the intracellular concentrations of 193 structurally and functionally diverse water-soluble metabolites within S. cerevisiae.

“Here, we used liquid chromatography coupled with tandem mass spectrometry method of non-targeted metabolomics to compare the effects of these three geroprotectors on the intracellular metabolome of chronologically aging budding yeast.”

Read the full study here: https://doi.org/10.18632/oncotarget.27926

Oncotarget Volume 12, Issue 7: https://www.oncotarget.com/archive/v12/i7/

About Oncotarget:

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com/ or follow us:

SoundCloud - https://soundcloud.com/oncotarget

Facebook - https://www.facebook.com/Oncotarget/

Twitter - https://twitter.com/oncotarget

LinkedIn - https://www.linkedin.com/company/oncotarget

Instagram - https://www.instagram.com/oncotargetjrnl/

YouTube - https://www.youtube.com/oncotargetyoutube

Pinterest - https://www.pinterest.com/oncotarget/

Reddit - https://www.reddit.com/user/Oncotarget

Oncotarget is published by Impact Journals , LLC. Please visit https://www.impactjournals.com/ or connect with us @ImpactJrnls

Media Contact

18009220957

The American Association for Cancer Research (AACR) organizes an annual meeting program covering some of the most recent discoveries in cancer research. The conference aims to highlight work from the best minds in research and medicine from institutions all over the world. Oncotarget, exhibited by its publisher Impact Journals, will be participating virtually at the AACR Annual Meeting this year.

Visit the Oncotarget website: www.oncotarget.com

Visit the Impact Journals website: www.impactjournals.com

As of June 2020, Scopus released their latest 2019 Journal Rankings on Oncology. Oncotarget is among their highest rated (Q1) journals and ranked number one in total citations in oncology. The journal has published outstanding papers and reviews by authors including Bert Vogelstein, Peter K. Vogt, Pier Paolo Pandolfi, Arnold J. Levine, Brian Druker, and Carol Prives. Founding Oncotarget Editorial Board members include Nobel Laureates Andrew V. Schally and Gregg L. Semenza; Lasker Award recipients Alexander Varshavsky, Brian J. Druker, and Gregg L. Semenza; and 16 members of the US National Academy of Sciences. Oncotarget is indexed and archived in PubMed, PubMed Central, Scopus, EMBASE, and META (Chan Zuckerberg Initiative).

The 2021 AACR conference, a two-week online event, will take place from April 10-15 and May 17-21, 2021. Topics include population science and prevention, cancer biology, translational and clinical studies, survivorship, and advocacy.

In 2019, Oncotarget participated in the AACR Annual Meeting at the Georgia World Congress Center in Atlanta, Georgia, USA, and "AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics," at the Hynes Convention Center in Boston, Massachusetts, USA. The total registration count from the 2019 AACR Annual Meeting was over 21,000—nearly 16,000 of which were scientific attendees from all over the world.

Follow the Oncotarget Twitter account (@Oncotarget) for live updates about the conference using the #AACR21 hashtag.

About Oncotarget:

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit www.oncotarget.com or follow us:

SoundCloud - @oncotarget

Facebook - www.facebook.com/Oncotarget/

Twitter - twitter.com/oncotarget

LinkedIn - www.linkedin.com/company/oncotarget

Instagram - www.instagram.com/oncotargetjrnl/

YouTube - www.youtube.com/OncotargetYouTube

Pinterest - www.pinterest.com/oncotarget/

Reddit - www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957

Listen to short summaries of the latest oncology-focused research published in this week's issue of Oncotarget. https://www.oncotarget.com/archive/v12/i7/

Oncotarget Volume 12, Issue 7 features:

COVER PAPER:

"Caloric restriction creates a metabolic pattern of chronological aging delay that in budding yeast differs from the metabolic design established by two other geroprotectors"

https://doi.org/10.18632/oncotarget.27926

EDITORIAL:

"The long road to TRAIL therapy: a TRAILshort detour"

https://doi.org/10.18632/oncotarget.27902

RESEARCH PERSPECTIVE:

"The role of immune surveillance in malignant transformation of benign salivary gland tumors"

https://doi.org/10.18632/oncotarget.27900

RESEARCH PAPER:

"Differential expression of Vitamin D binding protein in thyroid cancer health disparities"

https://doi.org/10.18632/oncotarget.27920

RESEARCH PAPER:

"Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine"

https://doi.org/10.18632/oncotarget.27922

RESEARCH PAPER:

"Mutually exclusive lymphangiogenesis or perineural infiltration in human skin squamous-cell carcinoma"

https://doi.org/10.18632/oncotarget.27915

RESEARCH PAPER:

"Decreased expression of the translation factor eIF3e induces senescence in breast cancer cells via suppression of PARP1 and activation of mTORC1"

https://doi.org/10.18632/oncotarget.27923

RESEARCH PAPER:

"[18F]FDG and [18F]FES positron emission tomography for disease monitoring and assessment of anti-hormonal treatment eligibility in granulosa cell tumors of the ovary"

https://doi.org/10.18632/oncotarget.27925

RESEARCH PAPER:

"Effect of cell microenvironment on the drug sensitivity of hepatocellular cancer cells"

https://doi.org/10.18632/oncotarget.27910

RESEARCH PAPER:

"Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients"

https://doi.org/10.18632/oncotarget.27909

RESEARCH PAPER:

"The presence of polymorphisms in genes controlling neurotransmitter metabolism and disease prognosis in patients with prostate cancer: a possible link with schizophrenia"

https://doi.org/10.18632/oncotarget.27921

CASE REPORT:

"Prognostic significance of isochromosome 17q in hematologic malignancies"

https://doi.org/10.18632/oncotarget.27914

About Oncotarget:

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com/ or follow us:

SoundCloud - https://soundcloud.com/oncotarget

Facebook - https://www.facebook.com/Oncotarget/

Twitter - https://twitter.com/oncotarget

LinkedIn - https://www.linkedin.com/company/oncotarget

Instagram - https://www.instagram.com/oncotargetjrnl/

YouTube - https://www.youtube.com/oncotargetyoutube

Pinterest - https://www.pinterest.com/oncotarget/

Reddit - https://www.reddit.com/user/Oncotarget

Oncotarget is published by Impact Journals , LLC. Please visit https://www.impactjournals.com/ or connect with us @ImpactJrnls

Media Contact

18009220957

In a trending paper published by Oncotarget on March 2, 2021, titled, “Quantitative proteome profiling stratifies fibroepithelial lesions of the breast,” researchers from India conducted a study to better characterize phyllodes tumors and other breast fibroepithelial lesions in order to improve diagnosis and treatment for patients.

To begin identifying the differentially expressed genes and proteins among FAD and PTs in benign, borderline, and malignant states, the researchers conducted quantitative global proteomics on Formalin-Fixed Paraffin-Embedded (FFPE) tissue sections. They conducted a principal component analysis of the protein expression matrix to identify the overlapping proteomic profiles among FELs.

“Interestingly, we observed FADs and benign PTs clustered together compared to borderline and malignant ones, albeit with overlapping protein expression profiles.”

Read the full study: doi.org/10.18632/oncotarget.27889

Oncotarget Volume 12, Issue 6: oncotarget.com/archive/v12/i6/

The Trending with Impact series highlights Oncotarget publications attracting higher visibility among readers around the world online, in the news, and on social media—beyond normal readership levels.

More from Trending with Impact: https://www.oncotarget.org/tag/trending-with-impact/

About Oncotarget:

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit www.oncotarget.com or follow us:

SoundCloud - @oncotarget

Facebook - www.facebook.com/Oncotarget/

Twitter - twitter.com/oncotarget

LinkedIn - www.linkedin.com/company/oncotarget

Instagram - www.instagram.com/oncotargetjrnl/

YouTube - www.youtube.com/OncotargetYouTube

Pinterest - www.pinterest.com/oncotarget/

Reddit - www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957x105

Oncotarget published "Quantitative proteome profiling stratifies fibroepithelial lesions of the breast" which reported that the current grading system remains unreliable in differentiating these tumors due to histological heterogeneity and lack of appropriate markers to monitor the sudden and unpredictable malignant transformation of PTs.

The high- throughput quantitative proteomic analysis suggested that FAD and PTs form distinct clusters away from borderline and malignant though there exist marked differences between them.

Interestingly, over-expression of extracellular matrices related proteins and epithelial-mesenchymal transition markers in borderline PTs led these authors to hypothesize a model of deposition and degradation leading to ECM remodeling and EMT acquisition triggering its malignant transformation.

They also identified three candidate biomarkers such as MUCL1, HTRA1, and VEGDF uniquely expressed in FAD, borderline, and malignant PTs, respectively, which were further validated using immunohistochemistry.

The present Oncotarget work shed light on a brief mechanistic framework of PTs aggressive nature and present potential biomarkers to differentiate overlapping FELs that would be of practical utility in augmenting existing diagnosis and disease management for this rare tumor.

Dr. Lekha Dinesh Kumar and Dr. Prashant Kumar both from The CSIR-Centre for Cellular and Molecular Biology said, "Fibroepithelial lesions (FELs) of the breast are a group of biphasic tumors that are highly heterogeneous in terms of their morphological as well as biological features."

FADs are widespread tumors accounting for 68% of all breast masses and 44–94% of biopsied breast lesions.

A commonly encountered complication in diagnosis is the differentiation of FADs and benign PTs primarily contributed by the overlapping histologic and morphological characteristics between these lesions.

Several recurrently mutated genes unique to FAD and PTs, and several protein markers have also been investigated previously for their diagnostic utility and association with histological grade in FELs.

However, not much effort has been made to identify potential diagnostic biomarkers that could improve the diagnostic practice to classify PTs and differentiate them from FADs.

To this end, the authors employed iTRAQ based quantitative proteomics of FELs to extensively characterize the proteomic alterations across these tumors in order to identify potential biomarkers and distinctly stratify these overlapping tumors.

The Kumar/Kumar Research Team concluded in their Oncotarget Research Output, "this study provided a comprehensive profile of differentially regulated proteins across various subtypes of FELs. The presence of extensive ECM proteins and EMT markers led us to hypothesize a model of deposition and degradation of these proteins thus triggering ECM remodeling and EMT acquisition in borderline PTs leading to its malignant state. Enrichment of platelet degranulation factors in malignant PT indicates active angiogenesis during this transformation. Herein, our initial findings suggest that MUCL1, HTRA1, and VEGFD can be used as potential proteomic markers that could augment existing diagnosis, and help in monitoring the progression of the disease. Further characterization of FELs using different omics platforms would help in better understanding of the cellular and molecular events that would help in understanding the disease dynamics and thus better management of the disease."

Sign up for free Altmetric alerts about this article

DOI - https://doi.org/10.18632/oncotarget.27889

Full text - https://www.oncotarget.com/article/27889/text/

Correspondence to - Lekha Dinesh Kumar - [email protected] and Prashant Kumar - [email protected]

Keywords - breast tumors, fibroepithelial lesions, phyllodes, iTRAQ, quantitative proteomics

In the cover paper of this week's issue of Oncotarget, titled: "Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma," the aim of the researchers in this exploratory study was to characterize the genomic and neoantigen changes in 23 paired primary and recurrent HNSCC tumors.

Of the 23 patients in this study, 17 were male and 14 were tobacco smokers. The distribution of primary tumor location was nine in the oral cavity, seven in the oropharynx, six in the larynx, and one in the hypopharynx. The researchers note that all seven patients with an oropharyngeal primary tumor were HPV+. All 23 patients received some combination of traditional treatment.

“To understand the recurrent mutation effect between primary and recurrent/metastatic tumors, we extract recurrently mutated genes (>1 sample mutated gene) from primary and recurrent/metastatic samples, separately.”

Read the full study here: https://doi.org/10.18632/oncotarget.27907

Oncotarget Volume 12, Issue 6: https://www.oncotarget.com/archive/v12/i6/

About Oncotarget:

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit www.oncotarget.com or follow us:

SoundCloud - @oncotarget

Facebook - www.facebook.com/Oncotarget/

Twitter - twitter.com/oncotarget

LinkedIn - www.linkedin.com/company/oncotarget

Instagram - www.instagram.com/oncotargetjrnl/

YouTube - www.youtube.com/OncotargetYouTube

Pinterest - www.pinterest.com/oncotarget/

Reddit - www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957x105

Listen to short summaries of the latest oncology-focused research literature published in this week's issue of Oncotarget.

https://www.oncotarget.com/archive/v12/i6/

Oncotarget Volume 12, Issue 6 features:

COVER PAPER:

"Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma."

Institutions: Washington University in St. Louis, Columbia University, St. Louis Children’s Hospital, Siteman Cancer Center

Quote: “We characterized genomic and neoantigen changes between 23 paired primary and recurrent HNSCC tumors. Twenty-three biopsies from patients originally diagnosed with locally advanced disease were identified from the Washington University tumor bank.”

doi.org/10.18632/oncotarget.27907

EDITORIAL:

"Innovating and expanding weight loss strategies for breast cancer survivors."

Institution: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Quote: “Compared to those with ideal body weight, women who have excess weight experience inferior outcomes once diagnosed with breast cancer, despite standard local and adjuvant therapy [6].”

https://doi.org/10.18632/oncotarget.27898

RESEARCH PERSPECTIVE:

"Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies."

Institutions: The Johns Hopkins University School of Medicine, Dartmouth Geisel School of Medicine and Norris Cotton Cancer Center, Yale University, Stony Brook University Renaissance School of Medicine

Quote: “Here, we review PDAC pathogenesis as it relates to fundamental ARS [Alternative RNA splicing] biology, with an extension to implications for PDAC patient clinical management.”

doi.org/10.18632/oncotarget.27901

RESEARCH PAPER:

"A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas."

Institutions: Loma Linda University, University of Kansas

Quote: “Herein we describe our search for small molecule inhibitors that disrupt binding of E6 to caspase 8 using AlphaScreen technology™ (Perkin Elmer, Waltham, MA). This technology is a proximity-based platform for identifying hit compounds that perturb a specific interaction between two beaded proteins. Using this approach, we interrogated a library of over 5000 small molecules for compounds that antagonize E6 binding to caspase 8.”

doi.org/10.18632/oncotarget.27908

RESEARCH PAPER:

"Characterization of the inflammatory microenvironment and hepatic macrophage subsets in experimental hepatocellular carcinoma models."

Institution: Ghent University

Quote: “Here, we characterized the tumor microenvironment and the proportion and transcriptional profile of hepatic macrophages (Mφ) in two commonly used HCC mouse models.”

doi.org/10.18632/oncotarget.27906

RESEARCH PAPER:

"Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations."

Institutions: Tata Memorial Centre, Homi Bhabha National Institute

Quote: “We performed survival analyses of lung squamous cell carcinoma patients harboring therapeutically relevant alterations identified by whole exome sequencing and mass spectrometry-based validation across 430 lung squamous tumors.”

doi.org/10.18632/oncotarget.27905

About Oncotarget:

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit www.oncotarget.com or follow us:

SoundCloud - @oncotarget

Facebook - www.facebook.com/Oncotarget/

Twitter - twitter.com/oncotarget

LinkedIn - www.linkedin.com/company/oncotarget

Instagram - www.instagram.com/oncotargetjrnl/

YouTube - www.youtube.com/OncotargetYouTube

Pinterest - www.pinterest.com/oncotarget/

Reddit - www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957x105

In a trending paper published by Oncotarget on March 2, 2021, researchers conducted a study to better understand why young Andean people are disproportionately affected by hepatocellular carcinoma (HCC) than others around the world.

Hepatocellular carcinoma (HCC) is one of the most heterogeneous forms of cancer, and affects older patients commonly after they have had prolonged liver disease. However, among Andean people, half of the total patients who develop HCC are adolescents and young adults. Researchers—from Sorbonne Université, Institut Pasteur, Université de Rennes, and Université de Toulouse in France, and the Instituto Nacional de Enfermedades Neoplásicas in Peru—conducted a study to better understand HCC in Andean people.

“To deepen our understanding of the molecular determinants of the disease in this population, we conducted an integrative analysis of gene expression and DNA methylation in HCC developed by 74 Peruvian patients, including 39 adolescents and young adults.”

Read the full study: https://www.oncotarget.com/article/27890/text/

The Trending with Impact series highlights Oncotarget publications attracting higher visibility among readers around the world online, in the news, and on social media—beyond normal readership levels.

More from Trending with Impact: https://www.oncotarget.org/tag/trending-with-impact/

About Oncotarget:

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit www.oncotarget.com or follow us:

SoundCloud - @oncotarget

Facebook - www.facebook.com/Oncotarget/

Twitter - twitter.com/oncotarget

LinkedIn - www.linkedin.com/company/oncotarget

Instagram - www.instagram.com/oncotargetjrnl/

YouTube - www.youtube.com/OncotargetYouTube

Pinterest - www.pinterest.com/oncotarget/

Reddit - www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957x105

Oncotarget published this top-performing paper in 2018, when researchers compared the overall survival, average total healthcare costs, and resource utilization among patients with advanced cancers who received either standard care or precision, targeted oncology.

The researchers, from Intermountain Healthcare facilities (located in Utah and California, U.S.) and California’s Stanford University School of Medicine, conducted a well-read study published in 2018, titled: “Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs.” This paper currently presents with an Altmetric attention score of 484.

Read about the study: https://www.oncotarget.com/article/24384/text/

Top Oncotarget publications rated by Altmetric Attention Score: https://www.oncotarget.com/news/altmetric/

The Top-Performer series highlights research literature published in Oncotarget that has generated a high Altmetric score. Altmetric scores, located at the top-left of trending Oncotarget papers, provide an at-a-glance indication of the volume and type of online attention the research has received.

More from the Top-Performer series: https://www.oncotarget.org/tag/top-performer/

About Oncotarget:

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit www.oncotarget.com or follow us:

SoundCloud - @oncotarget

Facebook - www.facebook.com/Oncotarget/

Twitter - twitter.com/oncotarget

LinkedIn - www.linkedin.com/company/oncotarget

Instagram - www.instagram.com/oncotargetjrnl/

YouTube - www.youtube.com/OncotargetYouTube

Pinterest - www.pinterest.com/oncotarget/

Reddit - www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

18009220957x105